Alimera Sciences, Inc. (ALIM)

$ 4.91
-0.07 (-1.41%)
Symbol ALIM
Price $ 4.91
Beta 1.666
Volume Avg. 0.07M
Market Cap 0.034B
Shares () -
52 Week Range 3.94-12.25
1y Target Est -
DCF Unlevered ALIM DCF ->
DCF Levered ALIM LDCF ->
ROE 39.63% Strong Buy
ROA -2.07% Neutral
Operating Margin -
Debt / Equity 3899.00% Strong Buy
P/E -
P/B 22.63 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ALIM news

Mr. Richard Eiswirth
Drug Manufacturers—Specialty & Generic
Nasdaq Global Market

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 124 full-time employees. The firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The firm operates through U.S. and International segment. The firm focuses on diseases affecting the back of the eye or retina. The firm's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.